Clinicians Continue to Enroll Children with NPC at Trial Sites in France, Spain,
Turkey, the United States and the United Kingdom -- Expansion to Australia Expected Soon
Clinical trial to evaluate the safety and tolerability of a potentially disease-modifying medicine for the treatment of sickle cell disease
In this role, he will lead research and development activities across all Cydan companies
Designation is first step to inclusion in Early Access to Medicines Scheme ("EAMS"), providing patients with faster access to innovative medicines
Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc.